A Phase III, Open-label, Multicentre, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-naive Patients With Stage IV Squamous Non-small Cell Lung Cancer
This randomized, open-label study will evaluate the safety and efficacy of atezolizumab
(MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel
compared with treatment with carboplatin + nab-paclitaxel in chemotherapy- naive
participants with Stage IV squamous NSCLC.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society